Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Canaccord ups Price Target to $7

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Mar 02, 2021 1:33pm

105 Views

Post# 32696207

RE:Canaccord ups Price Target to $7

I guess the legacy analysts are great at their job but the job must be something else than....

SPCEO1 wrote: Ed Nash has finally published a report and he upped the price target on THTX to $7 from $6. He is doing so primarily based on a better sales outlook for the legacy drugs. So, still not much credit for NASH or cancer although both are mentioned favorably.

<< Previous

Bullboard Posts

Next >>

Dynamic Funds Launches new ETF series on the TSX